The risk of exaggerated risk aversion—a life and death struggle for molecular imaging
November 11th, 2009In these days of managed care, there are always trade-offs between risks and value that need to be carefully weighted. As more and more use of PET imaging and biomarkers get validated, their combined value will be overwhelmingly appreciated.
Recent Updates
- QIBA PET Amyloid Biomarker Committee: Overview and 2016 Update Jan 17, 2017
- Developing a Safe and Effective Compounding Method for Hyperpolarized Pyruvate to be Used in the Clinical Evaluation of MR Molecular Imaging in Cancer Patients Jan 17, 2017
- Experts meet on State-of-the-Art Molecular Imaging in Cancer Biology and Therapy Feb 27, 2015
- Annexin A5 Imaging: An Academic Research - Clinical Trials and Theses Nov 11, 2014
- Quantitative imaging has the potential to accelerate research Oct 12, 2014
JLVMI LLC
JLVMI Consulting is a privately held consulting company that supports the development of molecular imaging agents from discovery and development through early stage clinical trials and commercialization. It also specializes in research and laboratory management for total safety and compliance.